Organogenesis (NASDAQ:ORGO) Shares Gap Up – Here’s What Happened

Organogenesis (NASDAQ:ORGO) shares gapped up before the market opened on Tuesday . The stock had previously closed at $4.83, but opened at $5.24. Organogenesis shares last traded at $5.0650, with a volume of 807,230 shares changing hands.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a research report on Monday, December 8th. Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, BTIG Research reiterated a “buy” rating and set a $9.00 price target on shares of Organogenesis in a research report on Monday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Organogenesis presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Organogenesis Trading Up 5.2%

The company has a market capitalization of $644.96 million, a PE ratio of -42.46 and a beta of 1.47. The company has a current ratio of 3.32, a quick ratio of 2.88 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $4.77 and a two-hundred day moving average of $4.46.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, November 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.11. The business had revenue of $150.86 million during the quarter, compared to analyst estimates of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. As a group, sell-side analysts anticipate that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Insider Activity at Organogenesis

In related news, Director Glenn H. Nussdorf sold 187,957 shares of Organogenesis stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $5.29, for a total value of $994,292.53. Following the transaction, the director owned 2,765,591 shares in the company, valued at $14,629,976.39. This trade represents a 6.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 300,000 shares of company stock worth $1,592,120. 33.00% of the stock is currently owned by company insiders.

Institutional Trading of Organogenesis

Institutional investors have recently added to or reduced their stakes in the business. Quarry LP bought a new position in shares of Organogenesis during the third quarter valued at about $25,000. State of Alaska Department of Revenue purchased a new stake in Organogenesis during the 3rd quarter valued at about $25,000. Farther Finance Advisors LLC bought a new position in shares of Organogenesis in the second quarter worth approximately $35,000. Ground Swell Capital LLC purchased a new stake in Organogenesis during the 2nd quarter valued at $39,000. Finally, Regent Peak Wealth Advisors LLC bought a new stake in Organogenesis in the 3rd quarter worth $51,000. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.